These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15236272)

  • 1. The pediatric research equity act and oncology.
    Hirschfeld S
    Pediatr Blood Cancer; 2004 Aug; 43(2):99-102. PubMed ID: 15236272
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 3. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulations and procedures for new drug evaluation and approval in China.
    Yin H
    Hum Gene Ther; 2006 Oct; 17(10):970-4. PubMed ID: 16958562
    [No Abstract]   [Full Text] [Related]  

  • 5. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 6. US regulation of pharmaceutical outcomes research.
    Burke LB
    Value Health; 2001; 4(1):5-7. PubMed ID: 11704971
    [No Abstract]   [Full Text] [Related]  

  • 7. Tricky FDA debate: should a risky drug be approved again?
    Mathews AW; Westphal SP
    Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
    Novak E; Allen PJ
    Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA to require pediatric studies for drugs commonly used in children.
    Miller JL
    Am J Health Syst Pharm; 1999 Feb; 56(3):203. PubMed ID: 10030499
    [No Abstract]   [Full Text] [Related]  

  • 10. Unlicensed and off-label drug use in children.
    Bavdekar SB; Gogtay NJ
    J Postgrad Med; 2005; 51(4):249-52. PubMed ID: 16388164
    [No Abstract]   [Full Text] [Related]  

  • 11. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 12. Current status of the FDA approval process: comparison of requirements for pediatric and adult patients.
    Robie-Suh KM
    Inflamm Bowel Dis; 1998 May; 4(2):103-4. PubMed ID: 9687212
    [No Abstract]   [Full Text] [Related]  

  • 13. Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
    O'Reilly J
    Food Drug Law J; 2005; 60(3):347-60. PubMed ID: 16304742
    [No Abstract]   [Full Text] [Related]  

  • 14. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 15. Readers' responses to "it is time for marijuana to be reclassified as something other than a schedule I drug".
    Fonfa AE
    MedGenMed; 2005; 7(4):35; author reply 34. PubMed ID: 16671183
    [No Abstract]   [Full Text] [Related]  

  • 16. Readers' responses to "it is time for marijuana to be reclassified as something other than a schedule I drug".
    Hernani EV
    MedGenMed; 2005; 7(4):35; author reply 34. PubMed ID: 16671182
    [No Abstract]   [Full Text] [Related]  

  • 17. Readers' responses to "it is time for marijuana to be reclassified as something other than a schedule I drug".
    Nederhood D
    MedGenMed; 2005; 7(4):35; author reply 34. PubMed ID: 16671179
    [No Abstract]   [Full Text] [Related]  

  • 18. Readers' responses to "it is time for marijuana to be reclassified as something other than a schedule I drug".
    Birnbaum R
    MedGenMed; 2005; 7(4):35; author reply 34. PubMed ID: 16671178
    [No Abstract]   [Full Text] [Related]  

  • 19. Readers' responses to "it is time for marijuana to be reclassified as something other than a schedule I drug".
    Archer FM
    MedGenMed; 2005; 7(4):35; author reply 34. PubMed ID: 16671177
    [No Abstract]   [Full Text] [Related]  

  • 20. Readers' responses to "it is time for marijuana to be reclassified as something other than a schedule I drug".
    Alvarez L
    MedGenMed; 2005; 7(4):35; author reply 34. PubMed ID: 16671176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.